Protocol Ledger

NCT04811092 · Phase III · TERMINATED

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Interventional Phase III clinical trial protocol NCT04811092 sponsored by Merck & Co. in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-18 Enrollment: 321 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04811092
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)321 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04811092
Protocol FieldVerified Registry Value
NCT IdentifierNCT04811092
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment321 participants (ACTUAL)
Registered Start Date2022-03-18
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI